Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343916 | 1.00 | ACHE (0.47) | ACHETDP1NOS3NOS1CHRNA7 | |
| SCHEMBL427794 | 1.00 | ACHE (0.47) | ACHETDP1NOS3NOS1CHRNA7 | |
| Ethane SCHEMBL11246075 | 0.97 | NOS3 (0.45) | ACHETDP1NOS3NOS1CHRNA7 | |
| SCHEMBL12807984 | 0.92 | PTPN5 (0.47) | ACHETDP1NOS3NOS1CHRNA7 | |
| SCHEMBL28483628 | 0.92 | PTPN5 (0.47) | ACHETDP1NOS3NOS1CHRNA7 | |
| SCHEMBL40655 | 0.87 | NOS3 (0.54) | TDP1NOS3NOS1UGT2B7ALDH1A1 | |
| SCHEMBL9331061 | 0.87 | NOS3 (0.54) | TDP1NOS3NOS1UGT2B7ALDH1A1 | |
| SCHEMBL9331190 | 0.87 | NOS3 (0.54) | TDP1NOS3NOS1UGT2B7ALDH1A1 | |
| SCHEMBL9331652 | 0.87 | NOS3 (0.54) | TDP1NOS3NOS1UGT2B7ALDH1A1 | |
| SCHEMBL8738417 | 0.86 | HPGD (0.52) | TDP1NOS3NOS1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108101740-B | Method for directly converting aromatic alkyne into chiral alcohol by one-pot method | 三峡大学 | 2022-02-01 | — | — | CN | claimed |
| CN-108101740-B | Method for directly converting aromatic alkyne into chiral alcohol by one-pot method | 三峡大学 | 2022-02-01 | — | — | CN | disclosed |
| CN-108101741-B | Method for synthesizing chiral alcohol by alkyne hydration/asymmetric hydrogenation tandem | 三峡大学 | 2021-06-29 | — | — | CN | disclosed |
| WO-2017136769-A1 | PEPTIDE DRUG CONJUGATES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-08-10 | — | — | WO | disclosed |
| EP-2812300-B1 | PROCESS FOR PREPARING CARBOXAMIDINE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-04-12 | — | — | EP | disclosed |
| EP-2115153-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BP CORP NORTH AMERICA INC (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2562175-A1 | 5-FLUORO PYRIMIDINE DERIVATIVES AS FUNGICIDES | Dow AgroSciences LLC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| WO-2010032770-A1 | CATALYST USED IN AN ALCOHOL HYDRIDE TRANSFER REACTION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR MANUFACTURING A CARBONYL GROUP-CONTAINING COMPOUND | 昭和電工株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
| EP-1934159-B1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1934159-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF SE (DE) | 2008-06-25 | — | — | EP | disclosed |
| EP-1808183-A2 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2007036570-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
| US-6365398-B1 | REACTING RACEMIC CARBOXYLIC ACID ESTER WITH RACEMIC ALCOHOL IN PRESENCE OF A CARBOXYL ESTER HYDROLASE | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1031629-A2 | Method of preparation of stereoisomeric carboxylic acid esters | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | ACHE 699/4885TDP1 4865/4885NOS3 2423/4885 |
| US-20090030235-A1 | METHOD FOR FRACTIONATING STEREOISOMERIC COMPOUNDS | ADH5, ADH1C, ADH1A | ACHE 2723/4885TDP1 4080/4885NOS3 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.